Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
An announcement from Adial Pharmaceuticals ( (ADIL) ) is now available.
Adial Pharmaceuticals, Inc. has announced a change in the date for its 2025 Annual Meeting of Stockholders to August 1, 2025. The record date for determining stockholders entitled to vote remains June 4, 2025. This change requires stockholders intending to solicit proxies for director nominees other than the company’s to comply with universal proxy rules by providing notice by June 26, 2025.
The most recent analyst rating on (ADIL) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Adial Pharmaceuticals stock, see the ADIL Stock Forecast page.
Spark’s Take on ADIL Stock
According to Spark, TipRanks’ AI Analyst, ADIL is a Underperform.
Adial Pharmaceuticals’ overall stock score is low due to ongoing financial struggles, including a lack of revenue and reliance on external funding. Technical analysis provides no strong directional signal, and valuation metrics are weak due to negative earnings. However, the recent FDA approval for AD04 offers a positive strategic outlook, but this is not enough to counteract the financial and operational challenges currently faced.
To see Spark’s full report on ADIL stock, click here.
More about Adial Pharmaceuticals
Average Trading Volume: 872,493
Technical Sentiment Signal: Sell
Current Market Cap: $3.05M
For an in-depth examination of ADIL stock, go to TipRanks’ Overview page.